A Phase 2 Study of Nivolumab in Combination With Either Rucaparib, Docetaxel, or Enzalutamide in Men With Castration-resistant Metastatic Prostate Cancer

Conditions

Prostate

Phase II

What is the purpose of this trial?

The purpose of this study is to determine which combination of Nivolumab plus either Rucaparib, Docetaxel, or Enzalutamide is the most effective in treating Castration-resistant Prostate Cancer that has spread

  • Trial with
    Bristol-Myers Squibb Research and Development
  • Start Date
    09/26/2018
  • End Date
    02/17/2020

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8348

Trial Image

For more information about this study, contact:

Matthew Piscatelli

  • Last Updated
    12/04/2018
  • Study HIC
    #2000022918